For this translational study downstream targets of the EGFR signalling network, namely pERK and pAKT, were centrally analyzed together with the tumor suppressor p53 in erlotinib-treated pancreatic cancer patients: pERK overexpression showed a negative correlation with OS. This evidence concerns the gene TP53 and pancreatic neoplasm.